apex rate was still 250 beats/min. Two intravenous doses of practolol had no effect. Digoxin was stopped and direct current shock, verapamil, disopyramide, and lignocaine were given to control her heart rate-all without success. When transferred to Guy's Hospital, aged 2 weeks, intracardiac electrophysiological studies showed the arrhythmia to be an ectopic upper His-bundle tachycardia with two components-a fast rate (250-300/min), which was sensitive to both lignocaine and disopyramide, and a slower rate (200-240/min Daily dose (mg/kg) Trough plasma concentrations of mexiletine and disopyramide with respect to weight-related daily doses. Open circles refer to data from case 1, closed circles to case 2. not be terminated either electrically or by drugs. Chronic oral therapy with mexiletine and disopyramide was started. Plasma drug concen'trations were monitored and the doses of both drugs were modified until plasma concentrations were similar to those known to be therapeutically effective in adults, using doses of 25 mg/kg (mexiletine) and 30 mg/kg (disopyramide) (figure). At this point her heart rate was stabilised at 170-180 beats/min. She has maintained this rate since she was discharged home, aged 5 months, contifnuing to thrive on both drugs.
Case 2-A 20-month-old boy was admitted to hospital with a febrile illness. While in hospital he developed a paroxysmal tachycardia (240/min) which was originally diagnosed as being supraventricular but was not controlled by digoxin, lignocaine, or disopyramide. Intracardiac electrophysiological studies showed the arrhythmia to be ventricular tachycardia responsive to bolus doses of lignocaine and disopyramide. He was therefore given intravenous lignocaine and disopyramide and changed rapidly to mexiletine and disopyramide by mouth. Dosage of these drugs was adjusted according to plasma drug concentrations, and his tachycardia was well controlled when concentrations were stabilised wi.hin the therapeutic range using doses of 15 mg/kg (mexiletine) and 20 mg/kg (disopyramide) (figure).
Comment
Daily adult maintenance doses of mexiletine and disopyramide are about 8-6 mg/kg and 5-7 mg/kg respectively. Plasma concentrations associated with therapeutic effect are in the range 0-75-2 mg/l1 (mexiletine) and 2-4 mg/12 (disopyramide). In these two children this dosage regimen produced very low plasma drug concentrations associated with a poor clinical response. Indeed, in both cases disopyramide and lignocaine (a drug with electrophysiological properties similar to mexiletine) had been abandoned as ineffective when they were given in conventional doses. Large doses were needed to control the tachycardia, at which time plasma drug concentrations were in the ranges produced by typical adult doses. Titration of these drugs according to plasma concentrations is therefore crucial for their safe and effective use in children. 
Patients, methods, and results
Serum IgE measurements were made with a commercially available paper radioimmunosorbent kit test (Phadebas).
(1) Initial studies on 30 consecutive outpatients with active, definite, or classical rheumatoid arthritis (RA)4 were carried out. Twenty-three were women and none was receiving gold or penicillamine therapy. The presence or absence of rheumatoid disease exacerbations or extra-articular manifestations was noted. Patients with a personal or a family history in a first-degree relative of asthma or eczema were excluded from this part of the study. Nineteen age-matched patients (17 women) with primary osteoarthritis (OA) were similarly studied for comparison. Serum IgE concentrations in RA (range 87-900 IU/ml, mean 354 IU/ml) were significantly higher than those in OA (range 11-137 IU/ml, mean 73-3 IU/ml) (P<0-001). The concentrations in the 13 rheumatoid patients with extra-articular complications of their disease (Sjogren's syndrome 7, Sjogrens syndrome+ cutaneous vasculitis 2, extensive subcutaneous nodules 2, upper limb oedema 1, and fever 1) did not differ significantly from rheumatoid patients without these complications.
(2) Serial serum IgE concentrations were measured before and during treatment with intramuscular gold injections (Myocrisin) in 17 patients with RA. Two of these had been excluded from the first study because of a family or personal history of hayfever. Myocrisin 50 mg weekly was given after incremental test doses. Serum IgE measurements were repeated at least at each three-monthly outpatient visit, or earlier in the case of gold toxicity, in parallel with other immunological and clinical measurements. Eight patients developed adverse reactions during gold therapy (table) Case 2-A 70-year-old woman was in excellent health until she arrived in Perth, Western Australia, in July 1978, after a flight from Great Britain. On arrival her left leg was numb and she experienced cramp in her calf after walking about 50 yards. There was a delay of three weeks before referral to hospital, by which time her claudication distance was 300-400 yards. Clinical examination showed classic signs of a left superficial femoral artery thrombosis. There were no signs of embolic disease. Because of her improved condition arteriography was not performed. She was advised to remain as mobile as possible on her return flight to Britain.
Case 3-A 44-year-old man underwent external iliac artery disobliteration in November 1977, which restored all leg and foot pulses. In February 1978 he undertook a five-day coach trip from Perth to Sydney, Australia, and found that he was unable to walk on arrival. He was referred in March 1978 on his return to Perth. Clinical examination failed to detect any pulses in his right leg. Arteriography and operation disclosed another thrombosis at the site of the disobliteration. Thrombectomy was performed. Subsequently all pulses were restored, and he was discharged well.
Comment
Two of these patients showed evidence of pre-existing arterial disease; in the third patient, this was not investigated. On long flights, such as those between Europe and Australia, patients with established peripheral arterial disease may benefit from being offered prophylaxis against arterial thrombosis as well as the more commonly recognised venous problems. Several factors, apart from being unable to walk about for many hours, may be concerned, particularly dehydration and excessive smoking that act by increasing blood viscosity and fibrinogen values.4
Thus travellers with peripheral arterial disease should be advised to remain as mobile and well hydrated as possible during prolonged travel. Sleeping tablets are probably contraindicated as these may exacerbate prolonged immobility and cause a concomitant fall in blood pressure. There may be a case for offering such patients aspirin or even low-dose heparin injections.
ADDENDUM-One of us (WMC) has been notified of a 68-year-old man who required an amputation below the left knee in Perth in July 1979 after arriving on the direct London-to-Perth flight. He had had a one-month history of left intermittent claudication. Disappearance of uraemic pruritus after lowering dialysate magnesium concentration Uraemic pruritus is well known in patients receiving chronic haemodialysis (CHD). Itching may be distressing and resistant to treatment. We report the case of a patient in whom all common treatments failed and whose pruritus completely disappeared after the concentration of magnesium in the dialysate was lowered.
Case report
A 59-year-old man with chronic glomerulonephritis had for two years been dialysed for six hours three times weekly with a 1-8 ml capillary kidney against a dialysate bath containing 1-0 mmol/l (2-4 mg/100 ml) magnesium. He had had pruritus before starting CHD but it worsened afterwards. Although aluminium hydroxide 12 g/day was needed to control serum phosphorus concentration, parathyroid hormone was only slightly raised at 6-7 mU/ml (normal range 2-6 mU/ml). Bone radiographs showed no uraemic osteopathy, so parathyroidectomy seemed not to be indicated. The itching, after briefly improving with antihistamine treatment, became worse. Ultraviolet phototherapy was tried without effect and was stopped after four weeks. Cholestyramine 4 g thrice daily also failed to give relief and was stopped after three weeks. We tried cimetidine, because it relieves pruritus in polycythaemia vera,' but without success. Beginning in January 1979 we lowered the magnesium concentration in the dialysate from 1.0 mmol/l to 0-2 mmol/l (2-4 mg/100 ml to 0-48 mg/100 ml). Consequently the serum magnesium concentration fell from 1-4 mmol/l (3-36 mg/100 ml) to a predialysis concentration of 0 57 mmol/l (1-36 mg/100 ml) and a postdialysis concentration of 0-37 mmol/l (0-88 mg/100 ml). After about a week the pruritus completely disappeared and had not relapsed after eight months.
